Abstract 585P
Background
In recent decades, progress in cancer diagnostics and treatments has led to improved early detection of cancer and more effective disease management, ultimately increasing survival rates. As more patients survive over the long term, the likelihood of developing multiple new cancers is rising. The objective is to present the patterns of dual primary malignancies observed in the cases registered in the year 2019 at Tata Memorial Centre(TMC) Mumbai.
Methods
This is a retrospective study conducted by HBCR at TMC, Mumbai. The HBCR team abstracts demographic and clinical data from the Electronic Medical Records including age, date of diagnosis, primary site, histology, clinical stage, treatment and follow-up details and entered into HBCR software. The primary site and histology are classified using ICD-O-3 and ICD-10 coding systems. For this study, cases registered at TMC Mumbai in the year 2019 are enrolled and followed up till December 2023. The study includes patients diagnosed with second primary malignancies(SPM) during this period, as well as those previously diagnosed and treated for a first primary malignancy outside and registered in TMC in 2019. The study adheres to IARC Rules, where SPM are identified based on histopathological or radiological evidence confirmed by clinicians and pathologist. The study distinguishes between synchronous and metachronous second primaries based on a time interval of 6 months.
Results
Total 37790 cancer cases are registered in TMC Mumbai in year 2019, of which 356 cases are diagnosed with second primary cancers. Among 356, synchronous are 147 and 209 are metachronous. Among the 356 cases of SPMs, 203 occurred in males and 153 in females. The most common site for primary tumour was Breast 73 cases followed by Buccal Mucosa 40 cases, Tongue 20 cases, Ovary 18 cases, Lung 14 cases and Prostate 14 cases. The most common site for second primary was Breast 61 cases, Lung 37 cases, Buccal Mucosa 21 cases, Tongue 19 cases, Ovary 17 cases and Thyroid 17 cases.
Conclusions
The early diagnosis of SPM should not be missed during follow-up and regular follow-up is essential for evaluating the survival outcomes of second primary malignancies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.